Abstract | INTRODUCTION: Despite availability of reliable guidelines development methods, the risk of producing less reliable documents may be higher when the guidelines are developed rapidly. OBJECTIVES: METHODS: We performed the search for documents, that considered antiviral therapies and contained a recommendations for clinicians. The quality of the guidelines was assessed using the AGREE II-Global Rating Scale Instrument and series of additional criteria. RESULTS: The analysis included 40 publications. The median of quality of documents assessed with the AGREE II-GRS tool was 2.0 (interquartile range 1.5-2.5). Most documents did not fulfill the rigour of guideline development quality criteria. The AGREE II-GRS scores did not differ significantly across the type of the document, issuing institution and the mode of publication. 75% of documents provided recommendations for the use of antiviral medications despite apparent lack of sufficient evidence supporting such treatments. Of the included documents, 75% were not updated within the 2 months after the publication of the first randomized controlled trial on COVID-19 antiviral therapy. CONCLUSIONS: Most guidelines or guidance documents published during the early phase of the COVID-19 pandemic were of poor quality, contained recommendations for the use of antiviral therapy for SARS-CoV-2 infection despite only very low quality of evidence available, and were not updated on a regular basis.
|
Authors | Filip Mejza, Wiktoria Lesniak, Roman Jaeschke |
Journal | Polish archives of internal medicine
(Pol Arch Intern Med)
Vol. 131
Issue 4
Pg. 356-360
(04 29 2021)
ISSN: 1897-9483 [Electronic] Poland |
PMID | 33720638
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antiviral Agents
(therapeutic use)
- COVID-19
- Humans
- Pandemics
- Practice Guidelines as Topic
- SARS-CoV-2
|